Previous 10 | Next 10 |
Unicycive Therapeutics press release (NASDAQ:UNCY): FY GAAP EPS of $0.86. FY Cash and cash equivalents of $16.6M For further details see: Unicycive Therapeutics GAAP EPS of $0.86
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of 2022 LOS ALTOS, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeuti...
LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Unicycive team, together with the Company’s Chief Executive O...
Unicycive to Present at Upcoming March Investor Conferences Presentations to highlight Company's novel treatments for kidney diseases PR Newswire LOS ALTOS, Calif. , March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a cli...
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting Data support potential efficacy and safety of Renazorb for the treatment of hyperphosphatemia in chronic kidney disease PR Newswire ...
Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire LOS ALTOS, Calif. , Jan. 10, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies f...
Unicycive Therapeutics (NASDAQ:UNCY) perks up 6.2% premarket after providing an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C in...
Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway On-track to submit New Drug Application in Q4 2022 PR Newswire LOS ALTOS, Calif. , Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-...
Unicycive Therapeutics (NASDAQ:UNCY): Q3 GAAP EPS of $0.37. As of September 30, 2021, cash and cash equivalents totaled $18 million. Press Release For further details see: Unicycive Therapeutics reports Q3 results
Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021 PR Newswire LOS ALTOS, Calif. , Nov. 11, 2021 /PRNewswire/ --...
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
Unicycive Therapeutics Inc. Website:
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Pate...
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a...